First-in-Class ICD Uses Single Lead With AF Sensing Capabilities

Biotronik’s Lumax DX system could help patients who may benefit from atrial sensing without pacing indication

 

February 25, 2013
Lumax 740 DX system, ICD

The Biotronik Lumax 740 DX system is a first-in-class implantable cardiac defibrillator (ICD) that utilizes a single lead with atrial sensing capabilities. Single-chamber ICDs utilize a lead to deliver an electrical shock to the heart when the heart rate becomes dangerously fast. For patients who have, or are at risk of developing atrial fibrillation (AF), a physician may consider implanting a dual-chamber ICD, which utilizes two leads and has pacemaker functions built in. 

Traditional standard single-chamber ICDs come with limitations. The devices are designed only to sense changes in ventricular rhythm and are unable to sense atrial arrhythmias, such as AF, correctly. This can result in an increased risk of an inappropriate shock or a stroke if AF is not detected.

The DX system expands the diagnostic capabilities of a standard single-chamber ICD with a single lead, in addition to featuring sophisticated sensors that allow for atrial monitoring and enhanced arrhythmia diagnosis. The system utilizes the LinoxsmartS DX lead. Based on proven technology, the LinoxsmartS DX utilizes an innovative floating atrial dipole. This allows physicians, for the first-time in an ICD, to capture atrial sensing capabilities with one lead. When combined with the Lumax 740 VR-T DX device — which has optimized circuitry — the system provides a reliable atrial signal. Additionally, its SMART Detection algorithms discriminate supraventricular tachycardias (SVTs), AF and atrial flutter to reduce the risk of inappropriate shocks.

The DX System also integrates with Biotronik’s Home Monitoring,  allowing physicians to remotely follow their DX patients’ clinical and device statuses daily, at anytime, anywhere in the world. The cellular-based system has demonstrated the ability to detect clinically relevant events, including silent, asymptomatic arrhythmias, and device related issues, allowing for earlier medical intervention. The diagnostic capabilities of the DX system combined with Home Monitoring makes this a simple, yet sophisticated system for cardiac rhythm management.

The DX System is approved in European Union and Japan. Biotronik expects to begin U.S. implants in late February/early March 2013.

For more information: www.biotronik.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.